Drug Trial Radar · NCT02835404
Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jul 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 2012
Primary completion
Jun 2017
Study completion Nov 2018
Sponsor
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the efficacy and complication of the treatment of pelvic external combined with 252-Cf neutron intracavitary radiotherapy with or without platinum in local advanced cervical cancer patients in the short and long term.
Conditions
- Cervical Cancer
- Complications
Interventions
NedaplatinDrug
Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
Pelvic External RadiotherapyRadiation
patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
252-Cf Neutron Intracavitary BrachytherapyRadiation
total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute toxicity eventsTime frame: Week 5 of Radiation Therapy (RT)
- Long-trem toxicity eventsTime frame: through study completion, an average of 5 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Chongqing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.